FAQ: Quantum BioPharma's Warrant Expiration and CVR Distribution Details
Summary
Quantum BioPharma announced the expiration of final hedge fund warrants from a 2020 financing and confirmed the October 27, 2025 record date for contingent value rights distribution to shareholders, which could provide a share of potential litigation proceeds.
What is the main announcement from Quantum BioPharma?
Quantum BioPharma announced the expiration of the final tranche of warrants issued to hedge funds and investment funds from a 2020 financing, and confirmed October 27, 2025 as the record date for distributing contingent value rights (CVRs) to Class B Subordinate Voting Shareholders.
What are the contingent value rights (CVRs) and what do they entitle shareholders to?
The CVRs entitle holders to a potential pro rata share of 10%-50% of any net proceeds from Quantum BioPharma’s $700 million litigation against CIBC World Markets, RBC Dominion Securities, and others, distributed on a one-for-one basis to Class B Subordinate Voting Shareholders.
When is the record date for the CVR distribution?
The record date for the CVR distribution is October 27, 2025.
How many warrants expired and what was their origin?
53,147 warrants expired, which were originally 3,454,543 pre-reverse-split warrants issued to hedge funds and investment funds as part of a 2020 financing.
What is Quantum BioPharma’s primary business focus?
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.
What is Lucid-MS and what does it treat?
Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation (the underlying mechanism of multiple sclerosis) in preclinical models, developed through its wholly owned subsidiary Lucid Psycheceuticals Inc.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness Inc.?
Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining 20.11% ownership (as of March 31, 2025) and receiving royalty payments of 7% of sales until payments total $250 million, then 3% in perpetuity, while keeping 100% rights for pharmaceutical and medical uses.
Where can investors find the latest news and updates about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
What other business activities does Quantum BioPharma engage in?
Through its wholly owned subsidiary FSD Strategic Investments Inc., Quantum BioPharma maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 259238